{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:02:06Z","timestamp":1789016526126,"version":"build-2803163510"},"reference-count":48,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The approach to the patient with relapsed or relapsed\/refractory multiple myeloma requires a careful evaluation of the results of previous treatments, the toxicities associated with it, and an assessment of prognostic factors. The majority of patients will have received prior therapy with drug combinations, including a proteasome inhibitor and an immune-modulatory agent. It is the physician\u2019s task to choose the right moment for the start of therapy and decide with the patient which goals need to be achieved. The choice of regimen is usually based on prior response, drugs already received, adverse effects, comorbidities of the patient, and expected efficacy and tolerability. Many double and triple drug combinations are available. In addition, promising new drugs such as pomalidomide, carfilzomib, and monoclonal antibodies are or will be available shortly, and other options can be explored in clinical trials. Finally, supportive care and palliative options need to be considered in later relapsed disease. Increasingly, it becomes important to consider the therapeutic options for the whole duration of the disease and integrate a systematic approach for the patient.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.508","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:11Z","timestamp":1555438391000},"page":"508-517","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":95,"title":["Management of multiple myeloma in the relapsed\/refractory patient"],"prefix":"10.1182","volume":"2017","author":[{"given":"Pieter","family":"Sonneveld","sequence":"first","affiliation":[{"name":"Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111705093885500_B1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.leu.2405016","article-title":"Clinically relevant end points and new drug approvals for myeloma","volume":"22","author":"Anderson","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"2019111705093885500_B2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111705093885500_B3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1634\/theoncologist.2014-0042","article-title":"European perspective on multiple myeloma treatment strategies in 2014","volume":"19","author":"Ludwig","year":"2014","journal-title":"Oncologist"},{"issue":"8","key":"2019111705093885500_B4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/blood-2017-03-726703","article-title":"How I treat first relapse of myeloma","volume":"130","author":"Harousseau","year":"2017","journal-title":"Blood"},{"issue":"20","key":"2019111705093885500_B5","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1200\/JCO.2013.53.0329","article-title":"Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and\/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death","volume":"32","author":"Moreau","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111705093885500_B6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"2019111705093885500_B7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/leu.2013.220","article-title":"Association of response endpoints with survival outcomes in multiple myeloma","volume":"28","author":"Lonial","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"2019111705093885500_B8","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111705093885500_B9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"2019111705093885500_B10","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/cncr.23326","article-title":"Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide\/lenalidomide therapy","volume":"112","author":"Sonneveld","year":"2008","journal-title":"Cancer"},{"issue":"13","key":"2019111705093885500_B11","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111705093885500_B12","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2019111705093885500_B13","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/leu.2010.175","article-title":"Treatment of patients with relapsed\/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies","volume":"24","author":"Dimopoulos","year":"2010","journal-title":"Leukemia"},{"issue":"12","key":"2019111705093885500_B14","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1080\/10428194.2016.1177181","article-title":"Pomalidomide plus low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials","volume":"57","author":"Siegel","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2019111705093885500_B15","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111705093885500_B16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111705093885500_B17","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111705093885500_B18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111705093885500_B19","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2013.293","article-title":"International Myeloma Working Group recommendations for global myeloma care","volume":"28","author":"Ludwig","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2019111705093885500_B20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"key":"2019111705093885500_B21","doi-asserted-by":"crossref","first-page":"vi133","DOI":"10.1093\/annonc\/mdt297","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Moreau","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111705093885500_B22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/10428190601001904","article-title":"An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma","volume":"48","author":"Prince","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"2019111705093885500_B23","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111705093885500_B24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2141.2009.07931.x","article-title":"Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide\/dexamethasone-refractory myeloma","volume":"148","author":"van de Donk","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111705093885500_B25","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/leu.2011.3","article-title":"Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement","volume":"25","author":"Dimopoulos","year":"2011","journal-title":"Leukemia"},{"issue":"12","key":"2019111705093885500_B26","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111705093885500_B27","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/leu.2014.60","article-title":"Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma","volume":"28","author":"Dimopoulos","year":"2014","journal-title":"Leukemia"},{"issue":"26","key":"2019111705093885500_B28","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111705093885500_B29","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111705093885500_B30","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3324\/haematol.13285","article-title":"Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma","volume":"93","author":"Moreau","year":"2008","journal-title":"Haematologica"},{"issue":"17","key":"2019111705093885500_B31","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111705093885500_B32","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bjh.12198","article-title":"A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma","volume":"160","author":"Petrucci","year":"2013","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111705093885500_B33","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2006-03-013086","article-title":"Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma","volume":"108","author":"Offidani","year":"2006","journal-title":"Blood"},{"issue":"34","key":"2019111705093885500_B34","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1200\/JCO.2009.22.2679","article-title":"Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed\/refractory multiple myeloma","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111705093885500_B35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"2019111705093885500_B36","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/annonc\/mdv325","article-title":"Carfilzomib and pomalidomide in patients with relapsed and\/or refractory multiple myeloma with baseline risk factors","volume":"26","author":"Dimopoulos","year":"2015","journal-title":"Ann Oncol"},{"issue":"17","key":"2019111705093885500_B37","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111705093885500_B38","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","author":"Dimopoulos","year":"2013","journal-title":"Lancet Oncol"},{"issue":"11","key":"2019111705093885500_B39","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"issue":"14","key":"2019111705093885500_B40","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2013-01-481325","article-title":"PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma","volume":"122","author":"Richardson","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2019111705093885500_B41","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"issue":"13","key":"2019111705093885500_B42","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"10027","key":"2019111705093885500_B43","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"2019111705093885500_B44","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3324\/haematol.2014.117531","article-title":"Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide","volume":"100","author":"Nijhof","year":"2015","journal-title":"Haematologica"},{"issue":"22","key":"2019111705093885500_B45","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/blood.V128.22.246.246","article-title":"Evaluation of minimal residual disease (MRD) in relapsed\/refractory multiple myeloma (RRMM) patients treated with daratumumab in combination with lenalidomide plus dexamethasone or bortezomib plus dexamethasone","volume":"128","author":"Avet-Loiseau","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2019111705093885500_B46","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.2016.71.1663","article-title":"Systematic literature review and network meta-analysis of treatment outcomes in relapsed and\/or refractory multiple myeloma","volume":"35","author":"van Beurden-Tan","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111705093885500_B47","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111705093885500_B48","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","article-title":"Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study","volume":"121","author":"Gahrton","year":"2013","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/508\/1250845\/hem00070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/508\/1250845\/hem00070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T05:09:56Z","timestamp":1573967396000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/508\/21173\/Management-of-multiple-myeloma-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.508","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}